AstraZeneca’s (AZN) stock has risen 18.4% so far this year, underperforming an increase of 23.4% for the industry, as seen in the chart below. AstraZeneca’s stock has, however, outperformed the sector as well as the S&P 500.AstraZeneca Stock Performance Image Source: Zacks Investment ResearchAstraZeneca boasts a diversified geographical footprint as well as product portfolio with several blockbuster medicines. AstraZeneca now has 12 blockbuster medicines in its portfolio with sales exceeding $1 billion, inc ...